<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793572</url>
  </required_header>
  <id_info>
    <org_study_id>2070.00</org_study_id>
    <secondary_id>NCI-2009-01473</secondary_id>
    <secondary_id>MPI X05251</secondary_id>
    <secondary_id>2070.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00793572</nct_id>
  </id_info>
  <brief_title>Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma</brief_title>
  <official_title>Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side-effects and anti-cancer effects of giving an autologous
      or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and
      bortezomib. Patients treated on this trial have newly diagnosed high-risk, relapsed, or
      refractory multiple myeloma (MM). Giving chemotherapy before an autologous stem cell
      transplant slows or stops the growth of cancer cells by preventing them from dividing or
      killing them. Stem cells that were harvested earlier from the patient's blood and frozen are
      then returned to the patient to replace the blood-forming cells that were destroyed by
      chemotherapy. Giving chemotherapy and total-body irradiation before an allogeneic donor stem
      cell transplant also prevents the patient's immune system from rejecting the donor's stem
      cells. Undergoing an autologous or syngeneic stem cell transplantation followed by an
      allogeneic donor stem cell transplant and bortezomib may be overall more effective in killing
      cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Progression-free survival (PFS) at 2 years after the autograft (=&lt; 50% in historic
      controls).

      SECONDARY OBJECTIVES:

      I. Overall survival (OS) at 2 years after the autograft.

      II. Non-relapse mortality (NRM) at 200 days and 1 year after allograft.

      III. Incidence of grades II-IV acute graft-versus-host-disease (GVHD) and chronic extensive
      GVHD.

      IV. Safety of bortezomib maintenance therapy after stem cell transplantation.

      OUTLINE:

      PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION: Patients undergo PBSC mobilization and
      collection using the preferred regimens at the participating institution.

      CONDITIONING CHEMOTHERAPY AND AUTOLOGOUS OR SYNGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
      (HSCT): Patients receive high-dose melphalan intravenously (IV) on day -2 followed by an
      autologous or syngeneic HSCT on day 0.

      NON-MYELOABLATIVE ALLOGENEIC HSCT: Beginning 40-180 days after autologous HSCT, patients
      receive 1 of the following regimens:

        1. HLA-IDENTICAL RELATED DONOR: Patients receive cyclosporine IV or orally (PO) twice daily
           (BID) starting on days -3 to 56, and taper until day 180. Patients then undergo
           total-body irradiation (TBI) and non-myeloablative allogeneic HSCT on day 0. Four to six
           hours after completion of allogeneic HSCT, patients receive mycophenolate mofetil (MMF)
           PO BID on days 0-27.

        2. HLA-UNRELATED DONOR: Patients receive fludarabine phosphate IV on days -4 to -2.
           Patients also receive cyclosporine IV or PO BID starting on days -3 to 100 and taper
           until day 180. Patients then undergo TBI and non-myeloablative allogeneic HSCT on day 0.
           Four to six hours after completion of allogeneic HSCT, patients receive MMF PO thrice
           daily (TID) on days 0-27 and then BID on days 27-40 with taper of MMF on days 40-96.

      MAINTENANCE THERAPY: Beginning 60-120 days after allogeneic HSCT, patients receive bortezomib
      subcutaneously (SC) on days 1 and 4 of 14-day cycles for 9 months or for up to 18 cycles in
      the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year and
      then annually for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>At 2 years after the autograft</time_frame>
    <description>Confidence intervals will be estimated.
Progressive disease:
Greater than 25% increase in serum (absolute increase must be ≥0.5 g/dL) or urine (absolute increase must be ≥200 mg/24h) M proteins compared to best response status after autologous transplant.
Appearance of new lytic bone lesions or plasmacytomas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grades II-IV Acute GVHD</measure>
    <time_frame>100 days post allo</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>1 year post allo</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Toxicities Related to Bortezomib Maintenance Therapy After the Stem Cell Transplantation</measure>
    <time_frame>Up to 100 days after the autograft or allograft</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>200 and 365 days after allo</time_frame>
    <description>Confidence intervals will be estimated. Assessed at 200 days and 1 year after allograft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>At 2 years after the autograft</time_frame>
    <description>Estimated by the method of Kaplan and Meier. Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Oforta</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Syngeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients must have received induction therapy (e.g., vincristine,
             doxorubicin, dexamethasone [VAD], thalidomide/dexamethasone) for a minimum of 4 cycles

          -  Must have the capacity to give informed consent

          -  Must have an human leukocyte antigen (HLA) genotypically identical sibling or a
             phenotypically matched relative or, at a minimum, a high likelihood of identifying an
             HLA-matched unrelated donor; the determination of availability of a suitable unrelated
             donor may be based on a World-Book search

          -  In addition, patients must meet at least one of the criteria A-I (A-G at time of
             diagnosis or pre-autograft):

               -  A) Any abnormal karyotype by metaphase analysis except for isolated t(11,14) and
                  constitutional cytogenetic abnormality

               -  B) Fluorescence in situ hybridization (FISH) translocation 4;14

               -  C) FISH translocation 14;16

               -  D) FISH deletion 17p

               -  E) Beta2-microglobulin &gt; 5.5 mg/L

               -  F) Cytogenetic hypodiploidy

               -  G) Plasmablastic morphology (&gt;= 2%)

          -  DONOR: HLA genotypically identical sibling or phenotypically matched relative OR

          -  DONOR: HLA phenotypically matched unrelated donor (according to Standard Practice HLA
             matching criteria, Grade #2.1)

               -  Matched HLA-A, B, C, DRB1, and DQB1 alleles by high resolution typing.

               -  Only a single allele disparity will be allowed for HLA-A, B, or C as defined by
                  high resolution typing

        Exclusion Criteria:

          -  Recurrent or non-responsive (less than partial response [PR]) MM after at least two
             different lines of conventional chemotherapy

          -  Progressive MM after a previous autograft

          -  Life expectancy severely limited by disease other than malignancy

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Females who are pregnant or breastfeeding

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Patients with active non-hematological malignancies (except non-melanoma skin cancers)
             or those with non-hematological malignancies (except non-melanoma skin cancers) who
             have been rendered with no evidence of disease, but have a greater than 20% chance of
             having disease recurrence within 5 years; this exclusion does not apply to patients
             with non-hematologic malignancies that do not require therapy

          -  Patients with fungal infection and radiological progression after receipt of
             amphotericin B or active triazole for greater than 1 month

          -  Patients with the following organ dysfunction:

               -  Symptomatic coronary artery disease or ejection fraction &lt; 40% or other cardiac
                  failure requiring therapy; myocardial infarction within 6 months prior to
                  enrollment or has New York Heart Association (NYHA) class III or IV heart
                  failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
                  electrocardiographic evidence of acute ischemia or active conduction system
                  abnormalities

               -  Ejection fraction is required if the patient has a history of anthracyclines or
                  history of cardiac disease

               -  Diffusing lung capacity for carbon monoxide (DLCO) &lt; 50%, forced expiratory
                  volume in 1 second (FEV) &lt; 50% and/or receiving supplementary continuous oxygen;
                  the Fred Hutchinson Cancer Research Center (FHCRC) principle investigator (PI) of
                  the study must approve of enrollment of all patients with pulmonary nodules

               -  Liver function abnormalities: Patient with clinical or laboratory evidence of
                  liver disease will be evaluated for the cause of liver disease, its clinical
                  severity in terms of liver function, bridging fibrosis, and the degree of portal
                  hypertension; the patient will be excluded if he/she is found to have fulminant
                  liver failure; cirrhosis of the liver with evidence of portal hypertension;
                  alcoholic hepatitis; esophageal varices; a history of bleeding esophageal
                  varices; hepatic encephalopathy; uncorrectable hepatic synthetic dysfunction
                  evinced by prolongation of the prothrombin time ascites related to portal
                  hypertension; bacterial or fungal liver abscess; biliary obstruction; chronic
                  viral hepatitis with total serum bilirubin &gt; 3 mg/dL; and symptomatic biliary
                  disease;

               -  Karnofsky score &lt; 70% for adult patients

          -  Patient with poorly controlled hypertension and on multiple antihypertensives

          -  Patients with current &gt;= grade 2 peripheral neuropathy

          -  Patient has an active bacterial or fungal infection unresponsive to medical therapy

          -  DONOR: Identical twin

          -  DONOR: Donors unwilling to donate PBSC

          -  DONOR: Pregnancy

          -  DONOR: Infection with HIV

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to G-CSF

          -  DONOR: Current serious systemic illness

          -  DONOR: Failure to meet FHCRC criteria for stem cell donation

          -  DONOR: Age &lt; 12 years

          -  DONOR: A positive anti-donor cytotoxic crossmatch

          -  DONOR: Patient and donor pairs must not be homozygous at mismatched allele
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Mielcarek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2017</results_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Marco Mielcarek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
          <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
          <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" lower_limit="32.8" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Confidence intervals will be estimated.
Progressive disease:
Greater than 25% increase in serum (absolute increase must be ≥0.5 g/dL) or urine (absolute increase must be ≥200 mg/24h) M proteins compared to best response status after autologous transplant.
Appearance of new lytic bone lesions or plasmacytomas.</description>
        <time_frame>At 2 years after the autograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
            <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Confidence intervals will be estimated.
Progressive disease:
Greater than 25% increase in serum (absolute increase must be ≥0.5 g/dL) or urine (absolute increase must be ≥200 mg/24h) M proteins compared to best response status after autologous transplant.
Appearance of new lytic bone lesions or plasmacytomas.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grades II-IV Acute GVHD</title>
        <description>Confidence intervals will be estimated.</description>
        <time_frame>100 days post allo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
            <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grades II-IV Acute GVHD</title>
          <description>Confidence intervals will be estimated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <description>Confidence intervals will be estimated.</description>
        <time_frame>1 year post allo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
            <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic GVHD</title>
          <description>Confidence intervals will be estimated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Toxicities Related to Bortezomib Maintenance Therapy After the Stem Cell Transplantation</title>
        <description>Confidence intervals will be estimated.</description>
        <time_frame>Up to 100 days after the autograft or allograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
            <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Toxicities Related to Bortezomib Maintenance Therapy After the Stem Cell Transplantation</title>
          <description>Confidence intervals will be estimated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>Confidence intervals will be estimated. Assessed at 200 days and 1 year after allograft.</description>
        <time_frame>200 and 365 days after allo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
            <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Confidence intervals will be estimated. Assessed at 200 days and 1 year after allograft.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 days post allo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year post allo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS</title>
        <description>Estimated by the method of Kaplan and Meier. Confidence intervals will be estimated.</description>
        <time_frame>At 2 years after the autograft</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
            <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>OS</title>
          <description>Estimated by the method of Kaplan and Meier. Confidence intervals will be estimated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: Conditioning through Day 100 post Auto; SAEs: Conditioning through Day 200 post Auto</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</title>
          <description>See Detailed Description
Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation
Bortezomib: Given SC
Cyclosporine: Given IV
Cyclosporine: Given PO
Fludarabine Phosphate: Given IV
Laboratory Biomarker Analysis: Correlative studies
Melphalan: Given IV
Mycophenolate Mofetil: Given PO
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation
Peripheral Blood Stem Cell Transplantation: Undergo transplantation
Syngeneic Bone Marrow Transplantation: Undergo transplantation
Total-Body Irradiation: Undergo radiotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders, Other (Microangiopathy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infections and infestations, Other (Serum)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pericardial tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marco Mielcarek</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>(206) 667-2827</phone>
      <email>mmielcar@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

